LJPC - ラホヤ・ファ―マシュ―ティカル (La Jolla Pharmaceutical Company) ラホヤ・ファ―マシュ―ティカル

 LJPCのチャート


 LJPCの企業情報

symbol LJPC
会社名 La Jolla Pharmaceutical Co. (ラホヤ・ファ―マシュ―ティカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ラ・ホイヤ・ファーマシューティカル(La Jolla Pharmaceutical Company)はバイオ医薬品企業である。同社は生命を脅かす疾患に罹患している患者の転帰を改善するための治療法の発見、開発および商業化に従事する。LJPC-501は、カテコールアミン耐性低血圧(CRH)の潜在的治療に対するアンギオテンシンIIの製剤である。同社は高出力ショック3(ATHOS)第III相試験の治療のためのアンギオテンシンIIと呼ばれる、CRHの治療のためのLJPC-501の第III相試験を開始した。LJPC-401は、遺伝性ヘモクロマトーシス、ベータサラセミア、鎌状赤血球症および骨髄異形成症候群のような鉄過剰によって特徴付けられる状態の潜在的な治療のための合成ヒトヘプシジンの製剤である。LJPC-30Sは、嚢胞性線維症やデュシェンヌ型筋ジストロフィーなどの稀な遺伝病、深刻な細菌感染の治療用の治療法に焦点を当てた次世代のゲンタマイシン誘導体プログラムである。   ラホヤ・ファ―マシュ―ティカルは米国のバイオ医薬品企業。慢性的な臓器不全や癌の治療薬の発見、開発、商業化に焦点を当てる。慢性腎疾患を有する患者の治療薬「GCS-100」、レニン ・アンジオテンシン・システムのペプチド作動薬「LJPC-501」、溶血性貧血などの鉄過剰の障害の治療として知られるヘプシジン「LJPC-401」がある。   
本社所在地 4550 Towne Centre Court San Diego CA 92121 USA
代表者氏名 Kevin C. Tang ケヴィン・C・タング
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-207-4264
設立年月日 32629
市場名 NASDAQ Small Cap
ipoyear 1994年
従業員数 309人
url www.ljpc.com
nasdaq_url https://www.nasdaq.com/symbol/ljpc
adr_tso
EBITDA EBITDA(百万ドル) -164.81500
終値(lastsale) 17.97
時価総額(marketcap) 471284831.97
時価総額 時価総額(百万ドル) 423.81540
売上高 売上高(百万ドル) 2.40200
企業価値(EV) 企業価値(EV)(百万ドル) 189.03140
当期純利益 当期純利益(百万ドル) -168.14000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 La Jolla Pharmaceutical Company revenues increased from $0K to $2.4M. Net loss increased from $50M to $103.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - other increase from $6.9M to $17.9M (expense) Stock-based Compensation in R&D increase from $5M to $11.1M (expense).

 LJPCのテクニカル分析


 LJPCのニュース

   La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe  2021/01/12 12:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) in the
   La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020  2020/11/09 22:35:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase), a biopharmaceutical company focused on commercializing its novel tetra
   La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress  2020/08/06 12:30:00 GlobeNewswire
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and…
   Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home  2020/06/29 11:16:43 Seeking Alpha
Merger activity decreased last week with one new deal announced. Tetraphase Pharmaceuticals agreed to be acquired by La Jolla Pharmaceutical Company. Waste Mana
   La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.  2020/06/24 11:30:00 GlobeNewswire
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
   La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe  2021/01/12 12:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) in the
   La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020  2020/11/09 22:35:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase), a biopharmaceutical company focused on commercializing its novel tetra
   La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress  2020/08/06 12:30:00 GlobeNewswire
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and…
   Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home  2020/06/29 11:16:43 Seeking Alpha
Merger activity decreased last week with one new deal announced. Tetraphase Pharmaceuticals agreed to be acquired by La Jolla Pharmaceutical Company. Waste Mana
   La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.  2020/06/24 11:30:00 GlobeNewswire
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
   La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020  2020/11/09 22:35:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase), a biopharmaceutical company focused on commercializing its novel tetra
   La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress  2020/08/06 12:30:00 GlobeNewswire
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and…
   Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home  2020/06/29 11:16:43 Seeking Alpha
Merger activity decreased last week with one new deal announced. Tetraphase Pharmaceuticals agreed to be acquired by La Jolla Pharmaceutical Company. Waste Mana
   La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.  2020/06/24 11:30:00 GlobeNewswire
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
   La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer  2020/06/22 16:14:54 Benzinga
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ラホヤ・ファ―マシュ―ティカル LJPC La Jolla Pharmaceutical Company)

 twitter  (公式ツイッターやCEOツイッターなど)